Establishing a single-sex controlled human
human-controlled Schistosoma masoni
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
03
2023
accepted:
13
07
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
Control of schistosomiasis depends on a single drug, praziquantel, with variable cure rates, high reinfection rates, and risk of drug resistance. A vaccine could transform schistosomiasis control. Preclinical data show that vaccine development is possible, but conventional vaccine efficacy trials require high incidence, long-term follow-up, and large sample size. Controlled human infection studies (CHI) can provide early efficacy data, allowing the selection of optimal candidates for further trials. A
Identifiants
pubmed: 37538934
doi: 10.1093/immadv/ltad010
pii: ltad010
pmc: PMC10396375
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ltad010Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
Déclaration de conflit d'intérêts
The authors declare that the research was conceptualized and protocol written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Infect Dis. 2016 Aug;16(8):971-9
pubmed: 27197551
Vaccine. 2016 Jun 3;34(26):2988-2991
pubmed: 27036511
Parasit Vectors. 2017 Jun 17;10(1):294
pubmed: 28623957
PLoS Negl Trop Dis. 2017 Oct 2;11(10):e0005982
pubmed: 28968470
Parasitology. 2014 Dec;141(14):1841-55
pubmed: 24932595
Lancet. 2014 May 17;383(9930):1707-8
pubmed: 24843875
J Clin Invest. 2014 Jul;124(7):3147-58
pubmed: 24911151
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1237-58
pubmed: 24127662
Scand J Immunol. 1992 Apr;35(4):429-37
pubmed: 1557613
Ann Trop Med Parasitol. 1967 Sep;61(3):294-301
pubmed: 5625699
PLoS Negl Trop Dis. 2021 Feb 11;15(2):e0009161
pubmed: 33571228
Science. 2016 Jan 1;351(6268):16-9
pubmed: 26721985
Nat Med. 2020 Mar;26(3):326-332
pubmed: 32066978
Front Immunol. 2021 Mar 04;12:635985
pubmed: 33746974
Lancet Infect Dis. 2015 Jul;15(7):840-51
pubmed: 26026195
Int J Environ Res Public Health. 2021 Nov 02;18(21):
pubmed: 34770050
J Am Acad Dermatol. 2015 Dec;73(6):929-44; quiz 945-6
pubmed: 26568337
Vaccine. 2019 Oct 8;37(43):6500-6509
pubmed: 31515141
Trans R Soc Trop Med Hyg. 2013 Jun;107(6):397-404
pubmed: 23596262
Am J Trop Med Hyg. 1996 Mar;54(3):265-70
pubmed: 8600763
Ann Intern Med. 2019 May 21;170(10):732-733
pubmed: 30615787
Glob Bioeth. 2022 Jul 4;33(1):78-102
pubmed: 35814190
Infect Immun. 2006 Jul;74(7):3979-86
pubmed: 16790771
Clin Infect Dis. 2019 May 2;68(10):1665-1674
pubmed: 30202872
Trends Parasitol. 2017 Mar;33(3):194-201
pubmed: 27865740
PLoS Negl Trop Dis. 2011 Sep;5(9):e1321
pubmed: 21949893
AAS Open Res. 2019 Aug 13;2:17
pubmed: 31819922
Parasitol Today. 1995 Aug;11(8):288-93
pubmed: 15275325
PLoS Negl Trop Dis. 2010 Mar 23;4(3):e637
pubmed: 20351784
Infect Dis Clin North Am. 2012 Jun;26(2):383-97
pubmed: 22632645
PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2865
pubmed: 25058013
Travel Med Infect Dis. 2011 Jan;9(1):6-24
pubmed: 21216199
J Infect Dis. 2018 Aug 24;218(7):1142-1146
pubmed: 29905805
AAS Open Res. 2018 Apr 18;1:2
pubmed: 30714021
Bull World Health Organ. 2018 Jan 1;96(1):59-65
pubmed: 29403101
PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005544
pubmed: 28410369
Clin Infect Dis. 2016 Nov 1;63(9):1151-1159
pubmed: 27470241
PLoS Negl Trop Dis. 2018 Dec 7;12(12):e0006968
pubmed: 30532268
PLoS Negl Trop Dis. 2011 Dec;5(12):e1396
pubmed: 22163056